

1 | **I. PRINCIPAL INVESTIGATOR AND RESEARCH SITE**

2
3 | **1. Sponsor Name (PI):** Carole Bitar, MD

4 | **2. Sub-PI:** Erin Boh, MD, PhD; Brittany Stumpf, MD; Katherine Brag, MD;

5 | **Collaborator:** Nakhle Saba, MD

6 | **3. # of Participants Sites:** 1, Tulane University

7 | **4: Participant Countries:** United States

8
9 | **II. PRODUCT INFORMATION**

10
11 | **1. Study Title:** A phase 2, open label single arm study for evaluating safety & efficacy of apremilast in
12 | the treatment of cutaneous disease in patients with recalcitrant dermatomyositis.

13
14 | **2. Clinical Phase:** Phase II clinical trial

15
16 | **3. Primary Celgene Product:** Apremilast

17
18 | **4. Secondary Celgene Product:** None

19
20 | **5. Tertiary Celgene Product:** None

21
22 | **6. Non- Celgene Products:** None

23
24
25 | **III. CONCEPT DESIGN AND RATIONAL**

26
27 | **1. Therapeutic Area:** Immunology

28
29 | **2. Specialty:** Connective tissue disease

30
31 | **3. Disease State:** Dermatomyositis

32
33 | **4. if Other Specify:** None

34
35 | **5. Study Rationale:** Dermatomyositis is an inflammatory disease that predominantly involves the skin
36 | with or without proximal muscle weakness. First line treatment for dermatomyositis is systemic
37 | steroids however due to long-term side effects, patients are usually treated with a steroid sparing
38 | agent. There is no known consensus on treatment guidelines for dermatomyositis and many anti-
39 | inflammatory medications have been successfully used. Tulane University is a referral center for
40 | recalcitrant dermatomyositis cases. We present the case of a 57 y.o female patient with multidrug
41 | recalcitrant dermatomyositis showing complete remission of her skin disease with apremilast and
42 | improvement of her muscle disease. This patient was diagnosed with dermatomyositis. Over a 6-year
43 | period, she was treated with adequate trials of multiple immunosuppressive agents, including
44 | hydroxychloroquine, mycophenolate mofetil, azathioprine, methotrexate, soriatane, Intravenous
45 | immunoglobulin (IVIG), tacrolimus, chlorambucil, infliximab and rituximab. For the last four years, we
46 | were unable to lower corticosteroids below 40 mg per day. Her disease continued to flare despite
47 | these therapies. Chronic steroid use resulted in insulin dependent diabetes mellitus as well as other
48 | steroids associated side effects. While on stable doses of mycophenolate mofetil, prednisone and
49 | rituximab, the patient developed arthritis and was started on apremilast 30 mg twice a day. Two
50 | months into her treatment she noticed significant improvement of her skin disease and then nearly

51 complete clearance of the skin. Her muscle weakness lagged behind and she noticed improvement
52 after 9 months of being on apremilast with normalization of her aldolase and CK. The patient was
53 able to wean off all immunosuppressive agents and prednisone. She was in remission for over 2
54 years and off all medications. She experienced a mild flare of skin disease recently and she resumed
55 apremilast only and cleared immediately and continues on apremilast as a monotherapy. Patient
56 experienced mild nausea and diarrhea with apremilast that improved four weeks into the treatment.
57 She was able to discontinue insulin, lose weight and she has continued to be clear of both skin and
58 muscle symptoms for over 1.5 years.

59 **This case will be presented as a poster presentation at the 2018 Annual Meeting of the**
60 **American Academy of Dermatology “Poster #: 6672 - Apremilast: a Potential Treatment for**
61 **Dermatomyositis.”**

62 Following our successful outcome, we initiated apremilast in 3 other patients with recalcitrant
63 dermatomyositis. Two of them had recalcitrant cutaneous disease and responded to add on therapy
64 of apremilast in 2 months with significant improvement of their skin disease. The third patient had
65 refractory dermatomyositis to several steroid-sparing agents and with severe muscle disease was
66 started on apremilast for arthritis. She experienced significant improvement of her muscle weakness
67 together with decrease in her muscle enzyme creatine kinase.

68 These very exciting findings triggered the idea of studying apremilast as an adjunct treatment for
69 recalcitrant cutaneous disease in dermatomyositis patients. This is a novel idea; apremilast was
70 never studied for dermatomyositis. Apremilast may have more advantages in dermatomyositis
71 compared to other immunosuppressive treatments. Dermatomyositis patients may have lung
72 involvement, and apremilast is an agent that doesn't have lung side effects in contrast to
73 methotrexate for example which is one of the main steroid sparing agents used for dermatomyositis.
74 The pathogenesis of dermatomyositis is multifactorial with environmental, genetic and immune factors
75 contribution.^[1] T helper-1 (Th1) and T helper-2 (Th2) immune pathways play a fundamental role in
76 dermatomyositis.^[2] There is increase in proinflammatory cytokines including tumor necrosis factor
77 alpha (TNF- α), interleukin (IL) 1, IL 6, and interferon (INF) α, γ shifting the immune balance to a Th1
78 response.^[1] Th1 immune response was also involved in the pathogenesis of interstitial pneumonia in
79 the setting of dermatomyositis.^[3] IL4 released by lymphocytes infiltrating skin and muscles in
80 dermatomyositis patients contributes to increase in Th2 response in conjunction with Th1 response.^[2]
81 Apremilast is a PD4-E inhibitor currently used for psoriasis and psoriatic arthritis.^[4] However, its
82 usage on patients with dermatomyositis has not been investigated.

83 By inhibiting PDE-4 apremilast increases the level of cyclic adenosine monophosphate (c-AMP),
84 leading to decreased expression of proinflammatory cytokines including TNF- α and INF- γ thus
85 inhibiting Th1 response.^[5] Apremilast can also block Th2 response by interfering with the level of IL6
86 secreted by type2 macrophages.^[4] While the mechanism of action of apremilast in dermatomyositis is
87 unknown, we suggest that apremilast can be a potential treatment option for dermatomyositis through
88 interfering with Th1 and Th2 response.

89 Apremilast is a well-tolerated oral medicine with transient gastrointestinal side effects.^[4] Apremilast
90 offers an additional treatment option for those patients with recalcitrant dermatomyositis,
91 unresponsive to more conventional therapy.

92
93 **6. Treatment and Dosing:** We will enroll patients seen at our facilities with a known diagnosis of
94 dermatomyositis who are still experiencing cutaneous disease after a trial of steroid-sparing agent
95 and/or systemic steroids.

96 We will add apremilast to their treatment regimen according to the approved dosage for psoriasis and
97 psoriatic arthritis: 10 mg orally one time on day 1, 10 mg orally twice daily on day 2, 10 mg orally in
98 AM and 20 mg orally in PM on day 3, 20 mg orally twice daily on day 4, 20 mg orally in AM and 30 mg
99 orally in PM on day 5, then 30 mg orally twice daily thereafter.

101 **7. Brief Study Synopsis:** With limited treatment options available for dermatomyositis, we
102 hypothesize that apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, is a safe and efficacious add-
103 on treatment in patients with recalcitrant cutaneous dermatomyositis.

104 The study will investigate the efficacy, safety and toxicity of apremilast given at 30 mg twice daily to
105 patients with recalcitrant cutaneous dermatomyositis. Clinical response will be assessed at 1 and 3
106 months. Patients will also be evaluated for durability of their response for up to 6 months.

107 Treatment will be monitored with frequent clinical visits (0, 1, 3 and 6 months) and blood tests (CBC,
108 CMP, CK, aldolase). Treatment will be discontinued at disease progression or unacceptable adverse
109 events. Disease progression is defined as a 4 points increase in CDASI score, worsening of muscle
110 disease by MMT-8 score and 5 points increase in DLQI.

111 5 mm skin biopsies from lesional skin will be performed before treatment with apremilast and after 3
112 months of treatment for gene expression profiling and confirmatory immunohistochemical stains.

113 **8. Inclusion Criteria:**

- 114 • Must understand the risks and the benefits/purpose of the study and provide signed and dated
115 informed consent.
- 116 • Must be 18 years at time of signing the informed consent form.
- 117 • Willing to participate in all required evaluations and procedures in the study including the ability
118 to swallow pills without difficulty.
- 119 • Patients must have a diagnosis of DM based upon the characteristic cutaneous findings
120 proposed by Sontheimer^[6] and/or a skin biopsy consistent with DM.
- 121 • Patients must be candidate for systemic therapy for their DM skin disease defined by
122 inadequate response to aggressive sun protection along with the use of potent topical
123 corticosteroids and/or immunomodulators.
- 124 • Patients with a diagnosis of dermatomyositis on steroid-sparing agent and/or systemic steroids
125 (maximum dose of prednisone 1mg/Kg) and still having cutaneous disease activity of at least 5
126 on the CDASI scale.
- 127 • If on immunosuppressive treatments and/or steroids, patients must be on stable doses for at
128 least 4 weeks (28 days).
- 129 • Patients must undergo age appropriate cancer screening.
- 130 • Females of childbearing potential (FCBP) must have a negative pregnancy test at screening
131 (day 0 of the study and every month throughout the study). While on investigational product
132 and for at least 28 days after taking the last dose of investigational product.

133 • **9. Exclusion Criteria:**

- 134 • Increasing or changing dose of topical therapy within 14 days of study day 0 (including but not
135 limited to topical corticosteroids, tacrolimus, pimecrolimus).
- 136 • Increasing or changing systemic steroids dosing within 28 days of study day 0.
- 137 • Increasing or changing dosing for concurrent therapy agents within 28 days or 5 half-lives of
138 the biologic agent, whichever is longer, before study day 0: methotrexate, azathioprine,
139 mycophenolate mofetil, hydroxychloroquine, dapsone, leflunomide, cyclosporine, biologic
140 agents (anti-TNFs), IVIG, rituximab.
- 141 • History of any clinically significant (as determined by the investigators) cardiac, endocrinologic,
142 pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major
143 uncontrolled disease.

- 148 • Any condition, including the presence of laboratory abnormalities, which places the patient at
149 unacceptable risk if he/she were to participate in the study or confounds the ability to interpret
150 data from the study.
- 151 • Pregnant or breastfeeding.
- 152 • Untreated Latent Mycobacterium tuberculosis infection or active tuberculosis infection as
153 indicated by a positive Purified Protein Derivative (PPD) skin test or T-spot.
- 154 • Any condition, including the presence of laboratory abnormalities that places the patient at
155 unacceptable risk if he/she were to participate in the study or confounds the ability to interpret
156 data from the study.
- 157 • Patients with acute dermatomyositis onset and rapid progression of muscle disease or
158 significant systemic involvement including pulmonary diseases associated with DM.
- 159 • Prior major surgery or major life-threatening medical illness within 2 weeks.
- 160 • Inflammatory bowel disease, malabsorption or any other gastrointestinal motility disorders that
161 limit the absorption of the study drug.
- 162 • Active hepatitis B or C infection with detectable viral nucleic acid in the blood or known Human
163 Immunodeficiency Virus (HIV) positivity.
- 164 • Prior history of suicide attempt at any time in the patient's lifetime prior to screening or
165 randomization, or major psychiatric illness requiring hospitalization within the last 3 years.
- 166 • Active substance abuse or a history of substance abuse within 6 months prior to screening.
- 167 • Use of any investigational drug within 4 weeks prior to randomization, or
168 5 pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).
- 169 • Prior treatment with apremilast.
- 170 • Any severe systemic illness requiring IV antibiotics within the two weeks prior to initiation of the
171 study drug.
- 172 • Malignancy or history of malignancy within the past four years, except for:
 - 173 ○ treated [ie, cured] basal cell or squamous cell in situ skin carcinomas;
 - 174 ○ treated [ie, cured] cervical intraepithelial neoplasia (CIN) or carcinoma in situ of cervix
175 with no evidence of recurrence within the previous 4 years.

176 **10. Sampling and correlative analysis**

177 Although, the proposed mechanism of action of apremilast is through PDE-4 inhibition resulting in c-
178 AMP upregulation, the exact biological process that leads to dermatological response in
179 dermatomyositis remains ill-defined. We propose to perform gene expression profiling (GEP) using
180 RNA sequencing on skin biopsies collected before and after treatment with apremilast. In addition, we
181 plan to confirm our GEP findings at the protein level using immunohistochemical (IHC) stains.
182
183
184

185 **A. Tissue sampling and preparation**

186 **a. Tissue collection**

187 5 mm punch biopsy from dermatomyositis skin lesions will be performed at baseline and another 5
188 mm punch biopsy will be performed at the 3-month time point. Each biopsy will be vertically split in
189 two pieces and snap frozen on dry ice then it will be stored at -80C for further analysis with RNA
190 sequencing and IHC stains.
191

192 **b. RNA extraction**

193

194 At the end of all timeline collections, each skin biopsy will be mechanically broken down followed
195 by mRNA extraction using the RNeasy extraction Kit from QIAGENzz. mRNA will then be stored
196 at -80°C for subsequent RNA sequencing as detailed below.
197

198 **B. Correlative Analysis**

200 **Determining the mechanism of action of apremilast in dermatomyositis.**

202 **a. Gene expression profiling**

203 RNA extracted from skin biopsies collected before and after *in vivo* treatment with apremilast (as
204 detailed above) will be subjected to RNA sequencing. Illumina strand-specific TruSeq libraries will be
205 prepared from the polyA selected RNA and subjected to 1x100 base sequencing on an Illumina
206 HiSeq2500 machine. The number of samples proposed here (10 samples before treatment and 10
207 samples after treatment) is expected to yield sufficient statistical power for this approach; smaller
208 numbers have been used in similar approaches to investigate drugs' mechanism of action (usually
209 three samples).^[7-9]

210 RNA-seq analysis will be performed in conjunction with the Tulane Cancer Crusaders Next
211 Generation Sequence Analysis Core (Tulane Cancer Center -
212 <https://tulane.edu/som/cancer/research/core-facilities/cancer-crusaders/>). Gene and isoform
213 expression will be determined using RSEM^[10] and differential expression will be analyzed using EB-
214 seq.^[11] Genes that are identified as differentially expressed between the two groups with a False
215 Discovery Rate (FDR) of < 0.05 will be subjected to analysis by *Ingenuity* (IPA, Redwood City, CA).
216 This analysis will group the identified genes into specific pathways, cell types, or disease process. A
217 similar approach will be conducted using *Gene Set Enrichment Analysis (GSEA)*. These experiments
218 and GEP analysis will be performed in conjunction with our collaborator's (Dr. Nakhle Saba) lab,
219 given his extensive experience in this field.^[12, 13]

221 **b. Protein analysis**

222 Information identified by Ingenuity or GSEA (signaling pathways, regulatory molecules, etc...) will be
223 verified using IHC staining on select samples.
224

226 **IV. OBJECTIVES AND ENDPOINTS**

228 **1.Primary Objective Description**

230 To determine the overall response rate (ORR) of apremilast in cutaneous disease of patients with
231 recalcitrant dermatomyositis at 3 months.

232 The ORR will be measured using the Cutaneous Dermatomyositis Activity and Severity Index
233 (CDASI) at months 0, 1, and 3.

234 CDASI is a validated tool to measure skin disease activity in dermatomyositis.^[14] ORR includes partial
235 and complete responses. Complete response is defined by a CDASI score of zero. Partial response
236 is defined by a decrease of CDASI score of at least 4 points. Calculation is performed as the CDASI
237 score at 1, and 3 month(s) minus the score at baseline.

238 All investigators (PI and Sub-Is) will be trained on how to screen the patients per the CDASI score
239 tool.

240 Photograph of skin rash will be taken at months 0,1 and 3 and compared to baseline.
241

242 **2. Secondary Objective(s) Description**

244 To determine the durability of responses for up to 6 months on apremilast for responders at 3 months.
245 The durability of responses includes partial and complete response durability.
246 The durability of response will be measured using the CDASI at 6 months minus CDASI at 3 months.
247 Complete response durability is defined as zero or minus difference between CDASI score at 6
248 months and CDASI score at 3 months. Partial response is defined as >4 points difference between
249 CDASI score at 6 months and CDASI score at 3 months.

250
251 We will assess the response of all patients at 6 months to identify possible delayed response.
252 Complete response is defined by a CDASI score of zero at 6 months. Partial response is defined by a
253 decrease of CDASI score of at least 4 points at 6 months compared to baseline. Calculation is
254 performed as the CDASI score at 6 month(s) minus the score at baseline.

255
256 Photograph of patient's rash will be taken at 6 months and compared to 3 months and baseline.

257
258 To determine the safety and toxicity of apremilast when administered at 30 mg twice daily in patients
259 with dermatomyositis. The safety assessment will include the assessment of adverse events, serious
260 adverse events, laboratory testing and physical examination.

261
262 An additional secondary endpoint will be to determine if patients who experience remission of their
263 disease can be maintained on apremilast as monotherapy.

264
265 To determine the patient quality of life using the Dermatology Life Quality Index (DLQI)^[15] at baseline,
266 1, 3 and 6 months.

267
268 Patient will be assessed 1 month after discontinuing apremilast (follow up visit) to assess change in
269 response post discontinuation of apremilast. Patients will be examined and, CDASI, MMT-8 and DLQI
270 will be performed. Photograph of patient's rash will be taken. CBC, CMP, CK, aldolase and urine
271 pregnancy test will be performed.

272 **3. Exploratory Objectives:**

273 We will measure muscle enzymes (creatin kinase (CK) and aldolase) at 0, 1, 3, and 6 month(s) of
274 apremilast in patients with muscle disease.

275 We will assess disease activity using the manual muscle testing-8 (MMT-8) in patients with muscle
276 disease.^[16]

277 Skin biopsies from lesional skin will be performed before treatment with apremilast and after 3 months
278 of treatment for gene expression profiling and IHC stain. IHC will be performed on the protein product
279 of the genes showing the largest fold change from the RNA-sequencing.

280 All investigators (PI and Sub-Is) will be trained on how to screen the patients per the MMT-8 score
281 tool.

282 **V. STUDY ENROLLMENT AND TIMELINES**

283
284 **1. # of Patients Expected to Enroll:** 10

285
286 **2. Date of planned FSI:** 04/02/2018

287
288 **3. Date of planned LSI:** 11/01/2018

289
290 **4. Date of planned LSO:** 05/01/2019

291

292

293

294 **5. Patient treatment duration (# months):** 6 months

295 **6. Is an interim Analysis Planned?** Yes

296 **7. Date on planned Interim Analysis:** 03/01/2019

297 **8. Date of planned final report:** 06/03/2019

298 **9. Are patients reported outcomes measured:** Yes

300 **VI. STATISTICAL PLAN:**

301 Results of the study will be analyzed using descriptive statistics:

- 302 • Proportion of patients with complete ORR at 1,3 months
- 303 • Proportion of patients with partial ORR at 1,3 months
- 304 • Proportion of patients with complete durability response at 6 months for the 3 months responders
- 305 • Proportion of patients with partial durability response at 6 months for the 3 months responders
- 306 • Proportion of patients with complete response at 6 months
- 307 • Proportion of patients with partial response at 6 months
- 308 • Mean change from baseline in muscle enzymes (CK and aldolase in patients with muscle disease)
- 309 • MMT-8 change will be calculated as mean change from baseline at 1,3 and 6 months
- 310 • DLQI change will be calculated by identifying the proportion of patients with minimal clinically important difference of at least 5 points.

311 Missing data will be handled using the last observation carried forward approach (LOCF).

312 GEP will be analyzed using inferential statistics with a False Discovery Rate (FDR) of < 0.05.

313 **VII. INFORMED CONSENT:**

314 The protocol and the informed consent will be reviewed by the Institutional Review Board (IRB) prior to the start of the study. The proposed form must contain a full explanation of the possible risks, benefits and alternate treatment options. It should be written in a way that is easily understandable and comprehensible by the patient. If the patients does not understand English or is not fluent in the language than appropriate translation must be made available. It should also indicate that by signature, the patient or the legal guardian (where appropriate), permits access to medical records by the sponsor and by representatives of FDA. The primary investigator (PI) will be responsible for obtaining written informed consent from the patient prior to the study. A copy of the signed informed consent will be given to the patient and a copy will be submitted to the sponsor.

315 **1. Risks of Apremilast**

316 The PI will monitor patients for side effects of Apremilast throughout the study period.

317 The most commonly reported side effects of apremilast include: headache, upper respiratory tract infections, nausea, vomiting and diarrhea. Most of these side effects are usually mild to moderate and resolve with continued treatment.

318 Depression has been reported with the use of apremilast. The PI will screen patients for any sign or symptom of depression using PHQ2 questionnaire.

343
344
345

2. Pregnancy Risks

346 The risks to an unborn child (fetus) or nursing child from apremilast are not known at this time.
347 Results of the animal and in vitro studies can be found in the IB.

348 Women of child bearing potential will be screened with urine pregnancy test at day zero of the study
349 and every month through out the study.

350
351 If a women of child bearing age engage in activity that could result in pregnancy, they must use one
352 of the approved options for birth control while taking the study drug and for at least 28 days after the
353 last dose of study drug.

354 When a female patient of childbearing potential's contraceptive measures or ability to become
355 pregnant changes at the time of study entry or at any time during the study, the Investigator will
356 educate the subject regarding options and correct and consistent use of effective contraceptive
357 methods in order to successfully prevent pregnancy.

358
359 Approved options for birth control are:

360 Option 1: Any one of the following: hormonal contraception (for example, birth control pills,
361 injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation
362 (tying your tubes); or a partner with a vasectomy

363 OR

364 Option 2: Male or female condom (latex condom or any nonlatex condom NOT made out of
365 natural [animal] membrane [for example, polyurethane]) PLUS one of the following additional
366 barrier methods: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c)
367 contraceptive sponge with spermicide.

368 In the event of any pregnancy, the PI will discontinue the study medication, and will follow on the
369 patient through out her pregnancy.

370 VIII. ADVERSE EVENT

371 An adverse event (AE) is any noxious, unintended, or untoward medical occurrence occurring at any
372 dose that may appear or worsen in a patient during the course of a study. It may be a new
373 intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the
374 patient's health, including laboratory test values (as specified by the criteria below), regardless of
375 etiology. Any medical condition that was present prior to study treatment and that remains unchanged
376 or improved should not be recorded as an AE. If there is a worsening of that medical condition this
377 should be considered an AE. A diagnosis or syndrome should be recorded on the AE page of the
378 Case Report Form (CRF) rather than the individual signs or symptoms of the diagnosis or syndrome.

379 All AEs will be recorded by the Investigator(s) from the time of signing the informed consent through
380 the end of the designated follow-up period.

381 1. Abnormal laboratory values defined as adverse events

382 An abnormal laboratory value is considered to be an AE if the laboratory abnormality is characterized
383 by any of the following:

- 384
- 385 • Results in discontinuation from the study.
 - 386 • Requires treatment, modification/interruption of study drug dose, or any other therapeutic intervention.

- Is judged by the Investigator(s) to be of significant clinical importance.

If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis or syndrome should be recorded on the AE page of the CRF. If the abnormality was not a part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE.

2. Serious adverse events

A serious adverse event (SAE) is any AE which:

- Results in death
- Is life-threatening (i.e., in the opinion of the Investigator(s) the patient is at immediate risk of death from the AE)
- Requires inpatient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity (a substantial disruption of the patient's ability to conduct normal life functions)
- Is a congenital anomaly/birth defect
- Constitutes an important medical event

Important medical events are defined as those occurrences that may not be immediately life threatening or result in death, hospitalization, or disability, but may jeopardize the patient or require medical or surgical intervention to prevent one of the other outcomes listed above. Medical and scientific judgment should be exercised in deciding whether such an AE should be considered serious.

Events not considered to be SAEs are hospitalizations which: were planned before entry into the clinical study; are for elective treatment of a condition unrelated to the studied indication or its treatment; occur on an emergency outpatient basis and do not result in admission (unless fulfilling other criteria above); are part of the normal treatment or monitoring of the studied indication and are not associated with any deterioration in condition.

If an AE is considered serious, both the AE pages of the CRF and the SAE Report Form must be completed.

For each SAE, the Investigator(s) will provide information on severity, start and stop dates, relationship to study drug, action taken regarding study drug, and outcome.

3. Classification of severity

For both AEs and SAEs, the investigator(s) must assess the severity of the event. The AEs will be evaluated for severity according to the following scale:

Grade 1 = Mild

Grade 2 = Moderate

Grade 3 = Severe

4. Classification of Relationship/Causality of adverse events (SAE/AE) to study drug

The Investigator(s) must determine the relationship between the administration of study drug and the occurrence of an AE/SAE as Not Suspected or Suspected as defined below:

Not suspected: The temporal relationship of the adverse event to study drug administration makes a **causal relationship**

unlikely or remote, or other medications, therapeutic interventions, or underlying conditions provide a sufficient explanation for the observed event

Suspected: The temporal relationship of the adverse event to study drug administration makes a **causal relationship possible**, and other medications, therapeutic interventions, or underlying conditions do not provide a sufficient explanation for the observed event.

424 **5. Immediate reporting of serious adverse events**

425 Any AE that meets the criterion for a SAE requires the completion of an SAE Report Form in addition
426 to being recorded on the AE pages of the CRF. The Investigator(s) is required to ensure that the data
427 on these forms is accurate and consistent. This applies to all SAEs, regardless of relationship to
428 study drug, that occur during the study, those made known to the Investigator(s) within 30 days after
429 a patient's last dose of study drug, and those made known to the investigator(s) at anytime that are
430 suspected of being related to study drug.

431 The SAE must be reported immediately (i.e., within 24 hours of the Investigators' knowledge of the
432 event) to Celgene Safety by facsimile. A written report (prepared by the Investigator(s) using an SAE
433 Report Form or a 3500A Medwatch form is to be faxed to Safety (see below for contact information).

434 **Celgene Drug Safety Contact Information:**

435 Celgene Corporation
436 Global Drug Safety and Risk Management
437 86 Morris Ave.
438 Summit, NJ 07901
439 Fax: (908) 673-9115
440 E-mail: drugsafety@celgene.com

442 The SAE report should provide a detailed description of the SAE. If a patient has died and an
443 autopsy has been performed, copies of the autopsy report and death certificate are to be sent to
444 Celgene as soon as these become available. Any follow-up data will be detailed in a subsequent
445 SAE Report Form or Medwatch form and sent to Celgene.

446 The Investigator(s) is responsible for informing the Institutional Review Board/Ethics Committee
447 (IRB/IEC) of the SAE and providing them with all relevant initial and follow-up information about the
448 event. The Investigator(s) must keep copies of all SAE information, including correspondence with
449 Celgene and the IRB/IEC, on file. All SAEs that have not resolved upon discontinuation of the
450 patient's participation in the study must be followed until either the event resolves completely,
451 stabilizes/resolves with sequelae, or returns to baseline (if a baseline value is available).

452 **6. Pregnancies**

453 Pregnancies and suspected pregnancies (including a positive pregnancy test regardless of age or
454 disease state) of a female or the female partner of a male patient occurring while the patient is on
455 study drug, or within 30 days of the patient's last dose of study drug, are considered immediately
456 reportable events. Study drug is to be discontinued immediately and the patient instructed to return
457 any unused portion of the study drug to the investigator(s). The pregnancy, suspected pregnancy, or

458 positive pregnancy test must be reported to Celgene Safety immediately facsimile using the
459 Pregnancy Report form provided by Celgene.

460 The female should be referred to an obstetrician-gynecologist experienced in reproductive toxicity for
461 further evaluation and counseling.

462 The Investigator(s) will follow the female patient until completion of the pregnancy, and must notify
463 Celgene Safety of the outcome of the pregnancy as a follow-up on the follow up Pregnancy Reporting
464 form.

465 If the outcome of the pregnancy meets the criteria for immediate classification as a SAE (i.e.,
466 spontaneous or therapeutic abortion [any congenital anomaly detected in an aborted fetus is to be
467 documented], stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus]), the
468 Investigator(s) should follow the procedures for reporting SAEs (i.e., report the event to Celgene
469 Safety by facsimile within 24 hours of the Investigator's knowledge of the event).

470 In the case of a live "normal" birth, Celgene Safety should be advised by facsimile within 24 hours of
471 the Investigator's knowledge of the event.

472 All neonatal deaths that occur within 30 days of birth should be reported, without regard to causality,
473 as SAEs. In addition, any infant death after 30 days that the Investigator(s) suspects is related to the
474 in utero exposure to the study drug should also be reported to Celgene Safety by facsimile within 24
475 hours of the Investigators' knowledge of the event.

476 If the female is found not to be pregnant, any determination regarding the patient's continued
477 participation in the study will be determined by the Investigator.

478

479 **7. Overdose**

480

481 Abuse, withdrawal, sensitivity, or toxicity to an investigational product should be reported as an
482 AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be
483 reported as an AE. Any sequela of an accidental or intentional overdose of an investigational product
484 should be reported as an AE.

485

486 If the sequela of an overdose is an SAE, then the sequela must be reported on
487 an SAE report form. The overdose resulting in the SAE should be identified as the cause of the event
488 on the SAE report form but should not be reported as an SAE itself.

489

490 In the event of an overdose, the patient should be monitored as appropriate and should receive
491 supportive measures as necessary. There is no known specific antidote for apremilast overdose.
492 Actual treatment should depend on the severity of the clinical situation and the judgment and
493 experience of the treating physician.

494

495 Overdose for this protocol, on a per dose basis, is defined as ingestion of any more than the amount
496 prescribed of apremilast (or matching placebo) tablets in any 24 hour period whether by accident or
497 intentionally.

498

499 **IX. PATIENT'S WITHDRAWAL**

500

501 The patient may withdraw from the study or withdrawn due to the many reasons:

- 502 • Loss to follow-up
- 503 • Adverse Event

- Non-Compliance
- Minimal/no therapeutic effect.
- Withdrawal of the patient by the investigator.
- Other reasons

Efforts should be made to follow-up patients with adverse events to know the final outcome of the event.

The patient and/or investigator, both have the right to terminate the patient's participation in the study. The reason for termination/withdrawal will be documented.

X. DATA MANAGEMENT

All data must be entered into the clinical data management system before initiating treatment. Electronic case report form (CRF) will be used for the collection of all study data entry at the clinical trial site. The PI will enter the data. All requested information must be entered in the CRF in a timely manner and the CRF for each visit must be completed during the visit. The completed CRF must be reviewed, signed and dated by the PI as well as any missing data should be recorded. Files containing electronic data will be password protected and encrypted and will be closed when computers are left unattended. Contact lists, recruitment records, or other documents that contain Protected Personally Identifiable Information (PII) will be stored securely in locked cabinets or rooms and access to key codes will be limited.

XI. PUBLICATION PLAN

1. Target Journal: JAAD

2. If Other Specify: JAMA

3. Date of Planned manuscript: September 2019

XII. SUPPORT REQUESTED FROM CELEGENE RESOURCES

1. Requesting Study Drug? Yes

2. Requesting Study funding? Yes

3. Support Requested from other companies? No

4. Non-Celegene Support Sources: None

XII. BUDGET

1. Currency Type: US Dollars.

3. Total requested Amount from Celgene: \$ 40,000

554
555
556
557
558

Schedule of Events

Procedure	Screening phase	Baseline (Day 0)	Month 1	Month 3	Month 6	Follow up visits
Informed Consent	X					
Demography	X					
Medical History	X	X				
Inclusion/Exclusion Criteria	X	X				
Photograph		X	X	X	X	
Hematology	X		X	X	X	X
Serum Chemistry	X		X	X	X	X
Muscle enzymes (CK, aldolase)	X		X	X	X	X
T-spot	X					
Skin biopsy		X		X		
Safety Assessments						
Adverse Events		X	X	X	X	X
Vital Signs	X	X	X	X	X	X
Physical Examination	X	X	X	X	X	X
Weight	X	X	X	X	X	X
Urine Pregnancy test (every month)	X	X	X	X	X	X
Contraception Education	X	X	X	X	X	X
Efficacy Assessments						
CDASI	X	X	X	X	X	X
MMT-8		X	X	X	X	X
DLQI		X	X	X	X	X
PHQ-2	X	X	X	X	X	X
Dispense ID (every month)		X	X	X	X	

559
560
561
562

Timeframe between screening phase and day 0 of the study should not exceed 1 month.

I. REFERENCES

563
564
565
566
567
568
569
570
571

- [1] Thompson C, Piguat V, Choy E. The pathogenesis of dermatomyositis. *The British journal of dermatology* 2017.
- [2] Giris M, Durmus H, Yetimler B *et al.* Elevated IL-4 and IFN-gamma Levels in Muscle Tissue of Patients with Dermatomyositis. *In vivo (Athens, Greece)* 2017; 31:657-660.
- [3] Oda K, Kotani T, Takeuchi T *et al.* Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. *Scientific reports* 2017; 7:1635.
- [4] Maier C, Ramming A, Bergmann C *et al.* Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. *Annals of the rheumatic diseases* 2017; 76:1133-1141.

572 [5] Hatemi G, Melikoglu M, Tunc R *et al.* Apremilast for Behcet's syndrome--a phase 2, placebo-
573 controlled study. *The New England journal of medicine* 2015; 372:1510-1518.

574 [6] Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic
575 aspects. *Dermatologic clinics* 2002; 20:387-408.

576 [7] Narla A, Dutt S, McAuley JR *et al.* Dexamethasone and lenalidomide have distinct functional
577 effects on erythropoiesis. *Blood* 2011; 118:2296-2304.

578 [8] Fiskus W, Saba N, Shen M *et al.* Auranofin induces lethal oxidative and endoplasmic reticulum
579 stress and exerts potent preclinical activity against chronic lymphocytic leukemia. *Cancer Res* 2014;
580 74:2520-2532.

581 [9] Rosenwald A, Chuang EY, Davis RE *et al.* Fludarabine treatment of patients with chronic
582 lymphocytic leukemia induces a p53-dependent gene expression response. *Blood* 2004; 104:1428-
583 1434.

584 [10] Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a
585 reference genome. *BMC bioinformatics* 2011; 12:323.

586 [11] Leng N, Dawson JA, Thomson JA *et al.* EBSeq: an empirical Bayes hierarchical model for
587 inference in RNA-seq experiments. *Bioinformatics (Oxford, England)* 2013; 29:1035-1043.

588 [12] Saba NS, Liu D, Herman SE *et al.* Pathogenic role of B-cell receptor signaling and canonical NF-
589 κB activation in mantle cell lymphoma. *Blood* 2016; 128:82-92.

590 [13] Saba NS, Wong DH, Tanios G *et al.* MALT1 inhibition is efficacious in both naive and ibrutinib-
591 resistant chronic lymphocytic leukemia. *Cancer research* 2017.

592 [14] Akbulut S, Yilmaz M, Yilmaz S. Graft-versus-host disease after liver transplantation: a
593 comprehensive literature review. *World journal of gastroenterology* 2012; 18:5240-5248.

594 [15] Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for
595 routine clinical use. *Clinical and experimental dermatology* 1994; 19:210-216.

596 [16] Rider LG, Werth VP, Huber AM *et al.* Measures of adult and juvenile dermatomyositis,
597 polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual
598 Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment
599 Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity
600 Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health
601 Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle
602 Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body
603 Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity
604 Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI),
605 Skindex, and Dermatology Life Quality Index (DLQI). *Arthritis care & research* 2011; 63 Suppl
606 11:S118-157.

607

608